Clinical trials: Endometrial Disease
Endometrial Hyperplasia
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
Researchers are looking for a better way to treat women with nonatypical endometrial hyperplasia (NAEH). Endometrial hyperplasia is a condition where the lining of the uterus (called the endometrium) becomes too thick.
- Trial name
- SUNFLOWER (NCT06904274)
- Testing
- BAY865028, Medroxyprogesterone acetate
- Where
- 38 sites in United States, Canada and 1 more
- Sponsor
- Bayer
Infertile
Receptivity Assessment of Homogeneous Endometrium in Late Follicle Phase
Twenty eight infertile women undergoing ultrasonographic endometrial assessment in the late follicle phase, fourteen of them with homogeneous echo endometrium (group 1) and other fourteen with trilaminar endometrium (group 2)…
- Trial name
- NCT01533350
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Shen-Zhen City Maternity and Child Healthcare Hospital
Endometrial Cancer
A Safety and Efficacy of CCRT With Paclitaxel as Adjuvant Therapy to Post-Operative Advanced Endometrial Cancer Patients
The purpose of this study is to determine whether post-operative concurrent chemoradiation with paclitaxel is effective and safe in the treatment of high risk postoperative endometrial cancer patients.
- Trial name
- NCT00373620
- Testing
- paclitaxel
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Korean Gynecologic Oncology Group
Endometrial Cancer
BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer
Phase II study: Safety and preliminary efficacy of BAT1308 combined with platinum-containing chemotherapy;Phase III study: Confirmatory safety and efficacy study of BAT1308 combined with platinum-containing chemotherapy for…
- Trial name
- NCT06321068
- Testing
- carboplatin, Paclitaxel, Recombinant humanized anti-PD-1 monoclonal antibody injection
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Bio-Thera Solutions
Endometrial Cancer
Biomarker Guided Treatment in Gynaecological Cancer
MoMaTEC2 aims to test, in clinically oriented studies, the applicability of already identified and promising molecular biomarkers, to promote individualisation of treatment for patients with endometrial cancer.
- Trial name
- Momatec2 (NCT02543710)
- Testing
- Biomarker (ER/PR) guided lymphadenectomy, Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
- Where
- 9 sites in Netherlands, Norway and 1 more
- Volunteers
- 1,300 people
- Sponsor
- Haukeland University Hospital
Recurrent Gynecological Cancer, Metastatic Cervical Cancer
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
This research study is evaluating the safety and effectiveness of 2 immunotherapy drugs in combination with radiation therapy as a possible treatment for recurrent or metastatic gynecologic cancer.
- Conditions
- Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer, Metastatic Vaginal Cancer
- Trial name
- NCT03277482
- Testing
- Durvalumab, Tremelimumab, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Relapsed or Refractory Germ Cell Tumours, Advanced Relapsed or Refractory Endometrial Cancer
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
This study is open to adults with advanced germ cell tumours, endometrial cancer, or ovarian cancer whose previous treatments were not successful.
- Conditions
- Advanced Relapsed or Refractory Germ Cell Tumours, Advanced Relapsed or Refractory Endometrial Cancer, Advanced Relapsed or Refractory Ovarian Cancer
- Trial name
- NCT07306559
- Testing
- BI 3820768
- Where
- 13 sites in United States, Belgium and 4 more
- Volunteers
- 187 people
- Sponsor
- Boehringer Ingelheim
Endometrial Cancer, Recurrent Endometrial Cancer
Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
The purpose of this study is to determine the effectiveness of LY3023414 in treating the participants type of cancer and to determine the types and severity of side effects caused by treatment with LY3023414.
- Trial name
- NCT02549989
- Testing
- LY3023414
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer, Ovarian Neoplasms
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
This study, ELU- FRα-1, was focused on adult subjects who have advanced, recurrent or refractory folate receptor alpha (FRα) overexpressing tumors considered to be topoisomerase 1 inhibitor-sensitive based on scientific…
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer
- Trial name
- NCT05001282
- Testing
- ELU001
- Where
- 18 sites in United States
- Volunteers
- 79 people
- Sponsor
- Elucida Oncology
Renal Cell Carcinoma, Ovarian Carcinoma
OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
The study hypothesis is that a lower starting dose of anticancer tablet treatments can lead to better treatment tolerability in older patients, while the benefits of treatment can be the same.
- Conditions
- Renal Cell Carcinoma, Ovarian Carcinoma, Thyroid Carcinoma, Breast Carcinoma
- Trial name
- OPTI-DOSE (NCT05949424)
- Testing
- Olaparib, Lenvatinib, Sunitinib
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- University Medical Center Groningen
Endometrial Carcinoma, Metastatic Carcinoma
Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)
The investigators hypothesize that the dual inhibition of mTORC1/mTORC2 by AZD2014 combined with inhibition of aromatase enzyme by anastrozole will act synergistically and may be an interesting therapeutic option for endometrial…
- Conditions
- Endometrial Carcinoma, Metastatic Carcinoma, Hormone Receptor Positive Tumor
- Trial name
- VICTORIA (NCT02730923)
- Testing
- AZD2014, Anastrozole
- Where
- 12 sites in France
- Volunteers
- 72 people
- Sponsor
- Centre Leon Berard
Endometrial Cancer, Sentinel Lymph Node
Intraoperative Examination of Sentinel Node in Endometrial Cancer (TRSGO-SLN-003)
More than half of the cases with macrometastatic sentinel lymph node (SLN) have non-SLN metastasis and leaving these nodes in-situ may impair the survival.
- Trial name
- TRSGOSLN003 (NCT04560491)
- Testing
- Intraoperative examination of sentinel node
- Where
- Turkey (Türkiye)
- Volunteers
- 208 people
- Sponsor
- Ankara University
Asherman Syndrome, Endometrial Polyp
Efficiency of INTERCOAT (Oxiplex/AP Gel) in Preventing Intrauterine Adhesion Formation in Hysteroscopic Surgery
The study purpose is to examine the influence of INTERCOAT in prevention of intra-uterine adhesions formation after any hysteroscopic surgery.
- Conditions
- Asherman Syndrome, Endometrial Polyp, Uterine Myoma
- Trial name
- NCT01637974
- Testing
- INTERCOAT administration
- Where
- Israel
- Volunteers
- 130 people
- Sponsor
- Carmel Medical Center
Carcinoma of the Endometrium, Hysterectomy
Lymphedema After Primary Surgery for Endometrial Cancer
The purposes of this study are to determine the prevalence, size and impact on quality of life of lymphedema of the lower extremities after primary radical surgery with hysterectomy +/- pelvic - and paraaortic lymphadenectomy in…
- Conditions
- Carcinoma of the Endometrium, Hysterectomy, Lymphadenectomy
- Trial name
- LASEC (NCT02115477)
- Testing
- Lymphadenectomy
- Where
- 16 sites in Sweden
- Volunteers
- 262 people
- Sponsor
- Preben Kjolhede, MD, professor
Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx).
- Conditions
- Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer
- Trial name
- POTENTIATE (NCT05827614)
- Testing
- BBI-355, Erlotinib, Futibatinib
- Where
- 16 sites in United States
- Volunteers
- 85 people
- Sponsor
- Boundless Bio, Inc.
Cervical Cancer, Endometrial Cancer
Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer
RATIONALE: Learning about the effect of nutritional supplements on quality of life in patients receiving chemotherapy for cancer may help doctors plan the best treatment.
- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer
- Trial name
- NCT00905658
- Testing
- therapeutic nutritional supplementation, standard follow-up care
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Centre Oscar Lambret
Endometrial Carcinoma, Ovarian Carcinoma
Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)
This trial is a Phase 1b/2a/3 trial designed to evaluate the safety and efficacy of adding oral AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to standard platinum-based chemotherapy…
- Conditions
- Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- AL3818 (NCT02584478)
- Testing
- AL3818, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD)
- Where
- 41 sites in United States, China and 4 more
- Volunteers
- 294 people
- Sponsor
- Advenchen Laboratories, LLC
Menopause, Osteoporosis
Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis
The purpose of this research study is to evaluate the safety and effectiveness of this investigational drug for the treatment of menopausal symptoms while protecting the endometrium (uterine lining) and preventing postmenopausal…
- Trial name
- NCT00808132
- Testing
- bazedoxifene 20 mg/ conjugated estrogens 0.45 mg, bazedoxifene 20 mg/ conjugated estrogens 0.625 mg, bazedoxifene 20 mg
- Where
- 178 sites in United States, Argentina and 10 more
- Volunteers
- 1,886 people
- Sponsor
- Pfizer
Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
This phase II trial studies the effects of the combination of olaparib and durvalumab, cediranib and durvalumab, olaparib and capivasertib, and cediranib alone in treating patients with endometrial cancer that has come back…
- Conditions
- Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma
- Trial name
- NCT03660826
- Testing
- Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy
- Where
- 761 sites in United States, Canada
- Volunteers
- 288 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Colon Cancer
Cancer Loyalty Card Study 2 (CLOCS-2)
Cancer is one of the leading causes of mortality worldwide and is responsible for an estimated 9.6 million deaths yearly. Cancer-related deaths can be reduced if patients are diagnosed and treated early.
- Conditions
- Pancreatic Cancer, Colon Cancer, Oesophageal Cancer, Stomach Cancer
- Trial name
- (CLOCS-2) (NCT06447064)
- Testing
- Cases & Controls
- Where
- United Kingdom
- Volunteers
- 2,900 people, healthy volunteers welcome
- Sponsor
- Imperial College London
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.